supported -driven medulloblastoma growth by sustaining ribosomal gene transcription and protein synthesis.
Evidence
This preclinical medulloblastoma study used CRISPR-Cas9 screening, genetic CDK8 loss, pharmacologic CDK8 inhibition, chromatin and transcriptional analyses, protein-synthesis assays, and in vivo combined CDK8 and mTOR inhibition.
Caveat
The therapeutic claim is based on experimental models, and the abstract does not report human clinical response or toxicity data.
Simplified
-driven medulloblastoma (MB) is a highly aggressive brain tumor with poor prognosis and limited treatment options. Through CRISPR-Cas9 screening, we identify the Mediator-associated kinase as a critical regulator of MYC-driven MB. Both genetic loss and pharmacological inhibition of CDK8 impair MB tumor growth. Moreover, we find that CDK8 cooperates with MYC to sustain the MYC-mediated translational program, as CDK8 depletion induces pronounced transcriptional changes in translation-associated gene sets, reduces ribosome biogenesis, and impairs protein synthesis. Mechanistically, CDK8 regulates the occupancy of RNA polymerase II at specific chromatin loci, facilitating epigenetic alterations that promote the transcription of ribosomal genes. Furthermore, combined inhibition of CDK8 and mTOR synergistically enhances therapeutic efficacy in vivo, leading to more pronounced tumor growth suppression. Overall, our findings establish a functional link between CDK8-mediated transcriptional regulation and mRNA translation, suggesting a promising therapeutic approach targeting protein synthesis for MYC-driven MB.
Key numbers
40 mg/kg
Tumor Growth Suppression
Dose of administered to mice for treatment
1 μM
Reduction in Protein Synthesis
Concentration of that reduced OPP signal indicating protein synthesis
Full Text
We can’t show the full text here under this license.
